Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences is showing strong potential for growth and success, driven by their progress in clinical trials and potential partnerships with major pharmaceutical companies like Gilead. With multiple exciting drug candidates in the pipeline and sufficient funding for the next decade, the company is well-positioned for long-term success. However, risks related to clinical development and potential delays should also be considered when evaluating their future prospects and stock valuation.

Bears say

Assembly Biosciences is facing challenges in its pipeline with its investigational therapies likely facing strong competition and a low PoS (probability of success). Additionally, one of its key candidates, ABI-4334, has been deprioritized and the company is now seeking a partner. While potential success in cholestatic liver diseases could bring in significant revenue, the lack of progress in other areas and the need for potential partnerships may weigh on the company's financials and stock performance.

Assembly Biosciences (ASMB) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Assembly Biosciences (ASMB) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.